Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Fijnheer

Showing results (61-70 of 106) with videos related to

Pageof 11
Sort By:
Nuclear Medicine Communications|October 7, 2015
Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation?Hugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
Skeletal Radiology|February 10, 2015
Does the presence of tumor-induced cortical bone destruction at CT have any prognostic value in newly diagnosed diffuse large B-cell lymphoma?Hugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
Journal of Computer Assisted Tomography|June 3, 2015
Residual Anatomical Disease in Diffuse Large B-Cell Lymphoma Patients With FDG-PET-Based Complete Response After First-Line R-CHOP Therapy: Does It Have Any Prognostic Value?Hugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
European Journal of Radiology|October 31, 2015
Tumor necrosis at FDG-PET is an independent predictor of outcome in diffuse large B-cell lymphomaHugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
European Journal of Haematology|October 15, 2014
Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphomaHugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
Plos One|June 12, 2013
Platelet activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as biomarkersJudith Brouwers, Rintis Noviyanti, Rob Fijnheer, et al.
Journal of Magnetic Resonance Imaging : JMRI|May 9, 2015
Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter studyAnnemieke S Littooij, Thomas C Kwee, Bart de Keizer, et al.
Journal of Computer Assisted Tomography|March 12, 2016
Where Does Diffuse Large B-Cell Lymphoma Relapse?Hugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 23, 2011
Plasma concentration of von Willebrand factor predicts mortality in patients on chronic renal replacement therapyNathalie C Péquériaux, Rob Fijnheer, Eugenie F Gemen, et al.
Acta Oncologica (Stockholm, Sweden)|September 30, 2014
Bone marrow biopsy in diffuse large B-cell lymphoma: useful or redundant test?Hugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
Pageof 11

Showing results (61-70 of 106) with videos related to

Sort By:
Pageof 11
Nuclear Medicine Communications|October 7, 2015
Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation?Hugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
Skeletal Radiology|February 10, 2015
Does the presence of tumor-induced cortical bone destruction at CT have any prognostic value in newly diagnosed diffuse large B-cell lymphoma?Hugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
Journal of Computer Assisted Tomography|June 3, 2015
Residual Anatomical Disease in Diffuse Large B-Cell Lymphoma Patients With FDG-PET-Based Complete Response After First-Line R-CHOP Therapy: Does It Have Any Prognostic Value?Hugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
European Journal of Radiology|October 31, 2015
Tumor necrosis at FDG-PET is an independent predictor of outcome in diffuse large B-cell lymphomaHugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
European Journal of Haematology|October 15, 2014
Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphomaHugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
Plos One|June 12, 2013
Platelet activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as biomarkersJudith Brouwers, Rintis Noviyanti, Rob Fijnheer, et al.
Journal of Magnetic Resonance Imaging : JMRI|May 9, 2015
Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter studyAnnemieke S Littooij, Thomas C Kwee, Bart de Keizer, et al.
Journal of Computer Assisted Tomography|March 12, 2016
Where Does Diffuse Large B-Cell Lymphoma Relapse?Hugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 23, 2011
Plasma concentration of von Willebrand factor predicts mortality in patients on chronic renal replacement therapyNathalie C Péquériaux, Rob Fijnheer, Eugenie F Gemen, et al.
Acta Oncologica (Stockholm, Sweden)|September 30, 2014
Bone marrow biopsy in diffuse large B-cell lymphoma: useful or redundant test?Hugo J A Adams, John M H de Klerk, Rob Fijnheer, et al.
Pageof 11